Aktuellt
SENASTE
Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which complements its current GARDskin test. We are positive about the expanded portfolio and see the early orders as a positive signal of market interest.
LÄS MER
